India develops affordable vaccine for rotavirus diarrhoea
New Delhi: Indian scientists have developed an affordable vaccine that
has shown strong efficacy in preventing rotavirus diarrhoea, the most
severe and lethal cause of childhood diarrhoea that kills over 100,000
children annually.
The vaccine `Rotovac` is the outcome
of public-private partnership between the Indian government`s Department
of Biotechnology (DBT) and pharma company Bharat Biotech.
Once
licensed by the Drugs Controller General of India (DCGI), the vaccine
will cost around Rs.54 per dose compared to the currently available
vaccine which costs Rs.2,250 per dose. Each child needs to take three
doses as part of vaccination.
"This is an important scientific
breakthrough against rotavirus infections, the most severe and lethal
cause of childhood diarrhoea, responsible for approximately 100,000
deaths of small children in India each year and rotavirus vaccine can
save 60,000 deaths," said DBT Secretary K. Vijay Raghavan.
"The
clinical results indicate that the vaccine, if licensed, could save the
lives of thousands of Indian children who get rotavirus diarrhoea every
year," he said.
As part of clinical trials, 7,000 infants from low income families in Delhi, Pune and Vellore were administered the vaccine.
"The
clinical trials show that the vaccine is efficacious in reducing severe
rotavirus diarrhoea by 56 percent during the first year of life, with
protection continuing into the second year of life while it reduces the
deaths by over 75 percent," said M.K. Bhan, former DBT secretary and
currently advisor to the Indian Academy of Paediatrics.
The
vaccine originated from an attenuated (weakened) strain of rotavirus
that was isolated from an Indian child at the All India Institute of
Medical Sciences in New Delhi in 1985-86.
"This is the first time
that India has developed a vaccine and it is totally indigenous as
strain was taken from an Indian infant, the vaccine was manufactures in
India and clinical trials were also done in India," said Bhan.
"With
its low price and strong efficacy, the vaccine has the potential to
significantly reduce the incidence of severe diarrhoea due to rotavirus
among children in India. It can also help in reducing infant deaths in
other developing countries," he added.
The oral vaccine can be given alongside routine immunization vaccines like polio vaccine and others.
"It
represents the successful research and development of a novel vaccine
from the developing world with global standards," said Krishna M. Ella,
chairman and managing director of Bharat Biotech.
Source-IANS